Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: A meta-analysis of randomized clinical trials

Medical Oncology

Volumn 28, Issue SUPPL. 1, 2011, Pages

  Ibrahim, Ezzeldin M ^a   Abouelkhair, Khaled M ^a  

^a International Medical Center   (Saudi Arabia)

Author keywords

Colorectal cancer; EGFR; K ras; KRAS; Metastatic; Panitumumab; Wild type

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB;

ACUTE HEART FAILURE; ARTICLE; CEREBROVASCULAR ACCIDENT; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HEART ARREST; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INJECTION SITE REACTION; INTESTINE PERFORATION; LIVER METASTASIS; LUNG EMBOLISM; META ANALYSIS; METASTASIS; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SKIN TOXICITY; TREATMENT OUTCOME;

EID: 84655176637     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9760-4     Document Type: Article

References (30)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 2 74 108 (Pubitemid 40372904)
2. S Kopetz GJ Chang MJ Overman C Eng DJ Sargent DW Larson 2009 Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy J Clin Oncol 27 22 3677 3683
3. I Chau D Cunningham 2009 Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 100 11 1704 1719
4. J Ortega CE Vigil C Chodkiewicz 2010 Current progress in targeted therapy for colorectal cancer Cancer Control 17 1 7 15
5. MP Cunningham H Thomas C Marks M Green Z Fan H Modjtahedi 2008 Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells Int J Oncol 33 5 1107 1113
6. MS Banck A Grothey 2009 Biomarkers of resistance to epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer Clin Cancer Res 15 24 7492 7501
7. HJ Andreyev AR Norman D Cunningham J Oates BR Dix BJ Iacopetta 2001 Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study Br J Cancer 85 5 692 696 (Pubitemid 32929467)
8. RG Amado M Wolf M Peeters E Van Cutsem S Siena DJ Freeman 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 10 1626 1634
9. EM Ibrahim JM Zekri BM Bin Sadiq 2010 Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations Int J Colorectal Dis 25 6 713 721
10. MK Parmar V Torri L Stewart 1998 Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 24 2815 2834 (Pubitemid 28562978)
11. M Egger G Davey Smith M Schneider C Minder 1997 Bias in meta-analysis detected by a simple, graphical test BMJ 315 7109 629 634 (Pubitemid 27387172)
12. J Lau JP Ioannidis CH Schmid 1997 Quantitative synthesis in systematic reviews Ann Intern Med 127 9 820 826 (Pubitemid 27465551)
13. JR Hecht E Mitchell T Chidiac C Scroggin C Hagenstad D Spigel 2009 A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 5 672 680
14. JY Douillard S Siena J Cassidy J Tabernero R Burkes M Barugel 2010 Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 31 4697 4705
15. M Peeters TJ Price A Cervantes AF Sobrero M Ducreux Y Hotko 2010 Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 31 4706 4713
16. RE Payne E Yague MJ Slade C Apostolopoulos LR Jiao B Ward 2009 Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients Pharmacogenomics 10 1 51 57
17. E Elez M Alsina J Tabernero 2010 Panitumumab-an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status Cancer Treat Rev 36 Suppl 1 S15 S16
18. DJ Freeman T Juan M Reiner JR Hecht NJ Meropol J Berlin 2008 Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone Clin Colorectal Cancer 7 3 184 190 (Pubitemid 351758148)
19. GM Keating 2010 Spotlight on panitumumab in metastatic colorectal cancer BioDrugs 24 4 275 278
20. GM Keating 2010 Panitumumab: a review of its use in metastatic colorectal cancer Drugs 70 8 1059 1078
21. R Adams T Maughan 2007 Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer Expert Rev Anticancer Ther 7 4 503 518 (Pubitemid 46681806)
22. R Nahta D Yu MC Hung GN Hortobagyi FJ Esteva 2006 Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer Nat Clin Pract Oncol 3 5 269 280 (Pubitemid 43731112)
23. Y Lu X Li K Liang R Luwor ZH Siddik GB Mills 2007 Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab Cancer Res 67 17 8240 8247 (Pubitemid 47395161)
24. F Di Nicolantonio M Martini F Molinari A Sartore-Bianchi S Arena P Saletti 2008 Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 35 5705 5712
25. E Hawkes I Chau DH Ilson D Cunningham 2009 Upper gastrointestinal malignancies: a new era in clinical colorectal cancer Clin Colorectal Cancer 8 4 185 189
26. J Tol M Koopman A Cats CJ Rodenburg GJ Creemers JG Schrama 2009 Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 6 563 572
27. LB Saltz HJ Lenz HL Kindler HS Hochster S Wadler PM Hoff 2007 Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25 29 4557 4561 (Pubitemid 350035312)
28. JL Marshall 2009 Vascular endothelial growth factor plus epidermal growth factor receptor dual targeted therapy in metastatic colorectal cancer: synergy or antagonism? J Oncol 2009 937305
29. ME Lacouture EP Mitchell B Piperdi MV Pillai H Shearer N Iannotti 2010 Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer J Clin Oncol 28 8 1351 1357
30. E Van Cutsem CH Kohne E Hitre J Zaluski CR Chang Chien A Makhson 2009 Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 1408 1417